Dai L, Fu H, Wang F, Guo R, Yang Y B, Lin Y, Chen K N
The First Department of Thoracic Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Peking University School of Oncology, Beijing 100142, China.
Zhonghua Yi Xue Za Zhi. 2018 Jun 5;98(21):1707-1712. doi: 10.3760/cma.j.issn.0376-2491.2018.21.017.
To evaluate the value of (18)F-FDG PET/CT in predicting long-term survival of esophageal squamous cell carcinoma(ESCC) before initial treatment. A total of 167 ESCC patients were retrospectively analyzed who underwent surgery between January 2010 and December 2014 in prospective database of Peking University Cancer Hospital Thoracic Surgery Department One, all cases were included according to inclusion and exclusion criteria.The relationship between SUVmax of the primary tumor and patients' age, gender, tumor location, tumor differentiation, tumor regression grade as well as long term survival were compared. The median follow-up time of the 167 cases was 46.9 months(ranging from 30.5 to 86.2 months), with 1 year and 3 years postoperatively being 95.1% and 68.4%, respectively.The SUVmax of the tumor was positively correlated with cT(<0.01), cN(=0.033), cTNM(=0.002) and pTNM(=0.003)of the tumor.Patients with SUVmax ≤6 obtained a survival significantly better compared with patients with SUVmax>6, the 3 years OS were 83.4 % vs 65.6% (=0.02) , and DFS were 82.4% vs 55.4%(=0.006), respectively.The multivariate regression analysis demonstrated that the SUVmax>6 before treatment was the independent prognostic factor for OS (=3, 95% 1.050-8.568) and DFS (=3.971, 95% 1.408-11.200) of the ESCC patients. The higher the (18)F-FDG PET/CT SUVmax of the ESCC primary tumor, the poorer survival of the patients. Therefore, SUVmax could be used as an indicator to predict long term survival of the ESCC patients before treatment.
评估¹⁸F-FDG PET/CT在预测食管鳞状细胞癌（ESCC）初始治疗前长期生存中的价值。回顾性分析了2010年1月至2014年12月在北京大学肿瘤医院胸外科一部前瞻性数据库中接受手术的167例ESCC患者，所有病例均根据纳入和排除标准纳入。比较了原发肿瘤的SUVmax与患者年龄、性别、肿瘤位置、肿瘤分化、肿瘤退缩分级以及长期生存之间的关系。167例患者的中位随访时间为46.9个月（范围30.5至86.2个月），术后1年和3年生存率分别为95.1%和68.4%。肿瘤的SUVmax与肿瘤的cT（<0.01）、cN（=0.033）、cTNM（=0.002）和pTNM（=0.003）呈正相关。SUVmax≤6的患者与SUVmax>6的患者相比，生存明显更好，3年总生存率分别为83.4%和65.6%（P=0.02），无病生存率分别为82.4%和55.4%（P=0.006）。多因素回归分析表明，治疗前SUVmax>6是ESCC患者总生存（P=3.95，95%可信区间1.050至8.568）和无病生存（P=3.971，95%可信区间1.408至11.200）的独立预后因素。ESCC原发肿瘤的¹⁸F-FDG PET/CT SUVmax越高，患者生存越差。因此SUVmax可作为预测ESCC患者治疗前长期生存的指标。
